title: Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor.
abstract: Dopamine D(3) receptors (Drd3) have been implicated in the control of responding by drug-related conditioned incentive stimuli. We review recent studies of the effects of Drd3 antagonists or partial agonists on the control of self-administration of intravenous (IV) cocaine, IV morphine and oral ethanol on reward-rich and lean schedules, in reinstatement tests, on second-order schedules and on the acquisition and expression of conditioned place preference (CPP) and conditioned motor activity. For comparison, related studies where conditioned stimuli are based on nutritional reward also are considered. When self-administration depends more heavily on conditioned cues for its maintenance, for example on second-order schedules or lean ratio schedules, Drd3 antagonists or partial agonists reduce responding. Although data are limited, similar effects may be seen for responding for cues based on drugs or nutritional rewards. Drd3 agents also block the ability of conditioned cues to reinstate responding for cocaine or food. Published results suggest that Drd3 plays a more important role in the expression than in the acquisition of a CPP or conditioned motor activity. The mechanism mediating the role of Drd3 in the control of responding by conditioned incentive stimuli remains unknown but it has been found that Drd3 receptors increase in number in the nucleus accumbens during conditioning. Perhaps Drd3 participates in the molecular mechanisms underlying the role of dopamine and of dopamine receptor subtypes in reward-related incentive learning.
authors.affiliation: Department of Psychology, and Centre for Neuroscience Studies, Queen's University, Kingston ON, K7L 3N6 Canada. Beninger@queensu.ca
authors.forename: R J
authors.initials: RJ
authors.lastname: Beninger
authors.forename: T J
authors.initials: TJ
authors.lastname: Banasikowski
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007858:Learning / Q000502:physiology*; D009042:Motivation; D050637:Receptors, Dopamine D3 / Q000502:physiology*; D012201:Reward
chemical_list: D050637:Receptors, Dopamine D3; D004298:Dopamine
references.citation: Neuropsychopharmacology. 2003 Nov;28(11):1903-15
references.pmid: 12915863
references.citation: Psychopharmacologia. 1967;11(1):88-94
references.pmid: 5596864
references.citation: Psychopharmacology (Berl). 1998 Dec;140(3):331-44
references.pmid: 9877013
references.citation: Neuropsychopharmacology. 2005 Apr;30(4):720-30
references.pmid: 15562293
references.citation: Brain Res. 1993 Nov 26;629(1):31-9
references.pmid: 8287278
references.citation: Pharmacol Biochem Behav. 2005 Dec;82(4):727-34
references.pmid: 16405981
references.citation: Brain Res Brain Res Rev. 1998 Dec;28(3):309-69
references.pmid: 9858756
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):573-82
references.pmid: 17272677
references.citation: CNS Drug Rev. 2007 Summer;13(2):240-59
references.pmid: 17627675
references.citation: Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):113-22
references.pmid: 2573022
references.citation: Psychopharmacology (Berl). 1996 Oct;127(3):213-24
references.pmid: 8912399
references.citation: Nature. 1999 Jul 22;400(6742):371-5
references.pmid: 10432116
references.citation: Neurotox Res. 2004;6(1):91-104
references.pmid: 15184110
references.citation: Science. 1997 Mar 14;275(5306):1593-9
references.pmid: 9054347
references.citation: J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78
references.pmid: 17170312
references.citation: Pavlov J Biol Sci. 1976 Oct-Dec;11(4):222-36
references.pmid: 1033507
references.citation: Synapse. 2003 Jun 1;48(3):154-6
references.pmid: 12645041
references.citation: Prog Neurobiol. 1998 Dec;56(6):613-72
references.pmid: 9871940
references.citation: Psychopharmacology (Berl). 1982;77(4):379-82
references.pmid: 6813901
references.citation: Neuroreport. 2003 Jan 20;14(1):93-8
references.pmid: 12544838
references.citation: Neuropsychopharmacology. 2003 Feb;28(2):329-38
references.pmid: 12589386
references.citation: Addict Biol. 2007 Mar;12(1):35-50
references.pmid: 17407496
references.citation: Prog Neurobiol. 1990;34(2):143-83
references.pmid: 1969668
references.citation: J Neurosci. 2002 Nov 1;22(21):9595-603
references.pmid: 12417684
references.citation: Brain Res. 1995 Mar 6;673(2):242-50
references.pmid: 7606438
references.citation: Eur J Neurosci. 2002 Jun;15(12):2016-26
references.pmid: 12099907
references.citation: Neuropsychopharmacology. 2003 Jun;28(6):1150-9
references.pmid: 12700684
references.citation: Neuropsychopharmacology. 2006 Jul;31(7):1393-405
references.pmid: 16205781
references.citation: Brain Res. 1986 Dec 3;399(1):33-41
references.pmid: 3026573
references.citation: Brain Res. 1983 Oct;287(2):173-96
references.pmid: 6357357
references.citation: Neuroreport. 2004 Oct 5;15(14):2245-9
references.pmid: 15371743
references.citation: Drug Alcohol Depend. 2006 Jan 4;81(1):63-70
references.pmid: 16005579
references.citation: Pharmacol Biochem Behav. 2006 Mar;83(3):456-64
references.pmid: 16631246
references.citation: Neurosci Lett. 1996 Jun 21;211(2):73-6
references.pmid: 8830847
references.citation: Neurosci Biobehav Rev. 2000 Jan;24(1):125-32
references.pmid: 10654668
references.citation: Brain Res Bull. 2003 Oct 15;61(6):595-601
references.pmid: 14519456
references.citation: Eur J Pharmacol. 1999 Jun 30;375(1-3):13-30
references.pmid: 10443561
references.citation: Neuroreport. 2002 Jan 21;13(1):173-6
references.pmid: 11924883
references.citation: Psychopharmacology (Berl). 1981;75(2):134-43
references.pmid: 6798603
references.citation: J Pharmacol Exp Ther. 2010 Nov;335(2):506-15
references.pmid: 20724485
references.citation: Science. 1978 Jul 21;201(4352):262-4
references.pmid: 566469
references.citation: Pharmacol Biochem Behav. 2008 Jun;89(4):499-507
references.pmid: 18329700
references.citation: FASEB J. 2006 Nov;20(13):2223-33
references.pmid: 17077299
references.citation: Behav Neurosci. 2008 Feb;122(1):129-39
references.pmid: 18298256
references.citation: Pharmacol Biochem Behav. 2005 May;81(1):190-7
references.pmid: 15894078
references.citation: Chembiochem. 2004 Apr 2;5(4):508-18
references.pmid: 15185375
references.citation: Neurosci Biobehav Rev. 1998 Mar;22(2):335-45
references.pmid: 9579323
references.citation: Neuropsychopharmacology. 2004 Aug;29(8):1479-87
references.pmid: 15100700
references.citation: Behav Neurosci. 2004 Dec;118(6):1324-30
references.pmid: 15598141
references.citation: J Pharmacol Exp Ther. 1973 Jul;186(1):18-30
references.pmid: 4198773
references.citation: Synapse. 2005 Jul;57(1):17-28
references.pmid: 15858839
references.citation: Nature. 1981 Nov 26;294(5839):366-8
references.pmid: 6273735
references.citation: Curr Opin Neurobiol. 1996 Apr;6(2):228-36
references.pmid: 8725965
references.citation: Behav Pharmacol. 2005 May;16(3):181-6
references.pmid: 15864073
references.citation: Eur J Neurosci. 2005 Jun;21(12):3427-38
references.pmid: 16026480
references.citation: J Neurosci. 2000 Oct 1;20(19):7489-95
references.pmid: 11007908
references.citation: Int J Neuropsychopharmacol. 2006 Oct;9(5):585-602
references.pmid: 16942635
references.citation: Psychopharmacology (Berl). 2007 Sep;193(4):475-86
references.pmid: 17492273
references.citation: Nat Med. 2003 Jun;9(6):762-7
references.pmid: 12740572
references.citation: Int J Neuropsychopharmacol. 2007 Apr;10(2):167-81
references.pmid: 16426478
references.citation: Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
references.pmid: 15960988
references.citation: Eur J Pharmacol. 2007 Mar 22;559(2-3):173-9
references.pmid: 17303116
references.citation: Pharmacol Rev. 1997 Sep;49(3):231-52
references.pmid: 9311022